A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

- No prior systemic treatment for unresectable stage IIIB or IV NSCLC

- Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb not
amenable to treatment with combined modality chemoradiation (advanced) or Stage IV
(metastatic) NSCLC

- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

- Measurable disease

- Adequate recovery from most recent systemic or local treatment for cancer

- Adequate organ function

- Life expectancy greater than or equal to (>/=) 12 weeks

- For female participants of childbearing potential and male participants, willingness
to use acceptable methods of contraception

Exclusion Criteria:

- Inability to swallow oral medication

- Women who are pregnant or lactating

- Symptomatic, untreated CNS metastases

- History of malignancy other than NSLCL within 5 years prior to screening with the
exception of malignancies with negligible risk of metastasis or death

- Significant cardiovascular disease, such as New York Heart Association cardiac disease
(Class II or greater), myocardial infarction, or cerebrovascular accident within 3
months prior to randomization, unstable arrhythmias, or unstable angina

- Known human immunodeficiency virus (HIV) positivity or autoimmune deficiency syndrome
(AIDS)-related illness

- Either a concurrent condition or history of a prior condition that places the patient
at unacceptable risk if he/she were treated with the study drug or confounds the
ability to interpret data from the study

- Inability to comply with other requirements of the protocol